DioTeX: Hemorrhage Diagnostics
Program: Biomedical Engineering
Trauma-induced internal hemorrhage is the leading cause of death for Americans under 46, causing around 50,000 American deaths annually as well as 90% of preventable U.S. troop deaths. Delays in diagnosis lead to larger blood loss and increased resuscitation requirements, making early detection of internal hemorrhage critical for patient survival. Devices such as the portable ultrasound may improve diagnostic accuracy in pre-hospital environments, but the high fragility and cost prohibits utilization by most combat units. Beyond the inaccessibility of the portable ultrasound, the high training requirements and variable accuracy between operators further prevents the deployment of these devices in the military. With the rapid advances in point-of-care technologies catalyzed by the COVID-19 pandemic, there is an opportunity to design a rapid biomarker-based test to diagnose internal hemorrhaging.
Through literature review, we identified a hemorrhage specific biomarker that is significantly upregulated during internal hemorrhage. We have developed a proof-of-concept lateral flow assay that detects elevated levels of this biomarker in solution. We are currently optimizing our assay to distinguish between normal and hemorrhaging biomarker levels. Additionally, with collaborators at UMD Medical Center, we are pursuing a data agreement to further characterize the release of syndecan-1 in response to trauma. Long term, we aim to create a field-ready lateral flow assay that can be used to diagnose patients in pre-hospital environments. By doing so, we will better inform evacuation decisions and improve emergency medical care to save lives.
Dr. Ariel Furer (Clinical Mentor)
Prof. Nicholas Durr (BME Mentor)
Rebecca Rosenberg, M.S. (Committee Member)
Dave Shade, J.D. (Committee Member)
Dr. Jason Cook (Committee Member)